Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives

Código QR

Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives

Ashwin Somasundaram, Timothy F Burns Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA Abstract: Lung cancer is the leading killer of both men and women in the US, and the 5-year survival remains poor. However, the approv...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Somasundaram A, Burns TF
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	Non-small cell lung cancer programmed death 1 programmed death ligand 1 tumor-infiltrating lymphocytes regulatory T cells. Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/1a44d40d230a4cbfab4a5686cc2ef827
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Clinical significance of programmed death 1 ligand-1 (CD274/PD-L1) and intra-tumoral CD8+ T-cell infiltration in stage II–III colorectal cancer
por: Chih-Yang Huang, et al.
Publicado: (2018)

Immunohistochemical expression of programmed death-ligand 1 and CD8 in glioblastomas
por: Dina Mohamed El Samman, et al.
Publicado: (2021)

Expression of Programmed Cell Death-1 (PD-1) and Its Ligand (PD-L1) in Breast Cancers and Its Association with Clinicopathological Parameters: A Study from North India
por: Anoushika Mehan, et al.
Publicado: (2021)

Sulforaphane enhances the antitumor response of chimeric antigen receptor T cells by regulating PD-1/PD-L1 pathway
por: Chunyi Shen, et al.
Publicado: (2021)

D-1 / PD-L1 EXPRESSION IN INVASIVE BREAST CARCINOMA / CANCER
por: Sammeen Salim, et al.
Publicado: (2021)

New targeted treatments for non-small-cell lung cancer – role of nivolumab
por: Zago G, et al.
Publicado: (2016)

Differential Role of PD-1 Expressed by Various Immune and Tumor Cells in the Tumor Immune Microenvironment: Expression, Function, Therapeutic Efficacy, and Resistance to Cancer Immunotherapy
por: Myeong Joon Kim, et al.
Publicado: (2021)

Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies
por: Wenwen Yang, et al.
Publicado: (2021)

Programmed death-ligand 1 expression and tumor-infiltrating lymphocytes in non-small cell lung cancer: association with clinicopathologic parameters
por: Gaurav Garg, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Pembrolizumab Plus Pemetrexed and Platinum Versus Chemotherapy Alone as First-Line Treatment in Metastatic Non-Squamous Non–Small Cell Lung Cancer: A Reconstruction of Partitioned Survival Model Based on Time Dependent Pricing Mechanism of Patient Assistance Program
por: Yuanyi Cai, et al.
Publicado: (2021)

Inhibition of PI3Kδ Differentially Regulates Poly I:C– and Human Metapneumovirus–Induced PD–L1 and PD–L2 Expression in Human Bronchial Epithelial Cells
por: Tomohiro Ogawa, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non–Small Cell Lung Cancer: Emerging Mechanisms and Perspectives
por: Inoue H, et al.
Publicado: (2020)

Expression of B7-H3 Correlates with PD-L1 and Poor Prognosis in Patients with Cervical Cancer [Corrigendum]
por: Zhang Q, et al.
Publicado: (2021)

Cancer Stem Cell-Like Circulating Tumor Cells Are Prognostic in Non-Small Cell Lung Cancer
por: Eva Obermayr, et al.
Publicado: (2021)

Pembrolizumab-Induced Adrenal Insufficiency in Patients with Untreated Advanced Non-Small Cell Lung Cancer: A Case Series
por: Kei Sonehara, et al.
Publicado: (2021)

Small cell transformation of non‐small cell lung cancer under immunotherapy: Case series and literature review
por: Takuma Imakita, et al.
Publicado: (2021)

Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
por: Barrows SM, et al.
Publicado: (2019)

Programmed cell death 5 transgenic mice attenuates adjuvant induced arthritis by 2 modifying the T lymphocytes balance
por: Yuan,Feng, et al.
Publicado: (2017)

A seven-gene prognostic model related to immune checkpoint PD-1 revealing overall survival in patients with lung adenocarcinoma
por: Wei Niu, et al.
Publicado: (2021)

Thoracic mesenchymal malignant tumors and programed cell death ligand‐1 status: Clinicopathologic and prognostic analysis of eight pulmonary sarcomatoid carcinomas and eight malignant mesotheliomas
por: Kanji Otsubo, et al.
Publicado: (2021)

BHLHE41/DEC2 Expression Induces Autophagic Cell Death in Lung Cancer Cells and Is Associated with Favorable Prognosis for Patients with Lung Adenocarcinoma
por: Toshiyuki Nagata, et al.
Publicado: (2021)

Neutrophil Extracellular Traps Promote T Cell Exhaustion in the Tumor Microenvironment
por: Christof Kaltenmeier, et al.
Publicado: (2021)

Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave
por: Xinfang Yu, et al.
Publicado: (2021)

Recent Progress of Ferroptosis in Lung Diseases
por: Shangjiang Yu, et al.
Publicado: (2021)

Successful treatment of locally advanced lung cancer using late concurrent chemoradiation therapy administered after immune checkpoint inhibitor plus platinum chemotherapy
por: Taichi Matsubara, et al.
Publicado: (2021)

Prospects for the development of adjuvant therapy for non-small cell lung cancer
por: K. K. Laktionov, et al.
Publicado: (2020)

Oligometastatic non-small-cell lung cancer: current treatment strategies
por: Richard PJ, et al.
Publicado: (2016)

Adaptive Radiation Therapy in the Treatment of Lung Cancer: An Overview of the Current State of the Field
por: Huzaifa Piperdi, et al.
Publicado: (2021)

Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib
por: Tan AC, et al.
Publicado: (2021)

Dual immunological blockade in the treatment of metastatic non-small cell lung cancer: reality and perspectives
por: Denis I. Yudin, et al.
Publicado: (2021)

Adjuvant targeted therapy for non-small cell lung cancer
por: Konstantin K. Laktionov, et al.
Publicado: (2020)

Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib
por: Jain RK, et al.
Publicado: (2017)

Immune Checkpoints OX40 and OX40L in Small-Cell Lung Cancer: Predict Prognosis and Modulate Immune Microenvironment
por: Peixin Chen, et al.
Publicado: (2021)

Ferroptosis in Lung Cancer: From Molecular Mechanisms to Prognostic and Therapeutic Opportunities
por: Peyman Tabnak, et al.
Publicado: (2021)

A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors
por: Nagasaka M, et al.
Publicado: (2019)

The association of aspirin use with overall survival of patients with inoperable non-small cell lung cancer: a retrospective study
por: Min-Chun Chuang, et al.
Publicado: (2021)

Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives
por: Giroux Leprieur E, et al.
Publicado: (2016)

Effect of antibiotic use on the efficacy of nivolumab in the treatment of advanced/metastatic non-small cell lung cancer: A meta-analysis
por: Huo Geng-wei, et al.
Publicado: (2021)

Construction of circRNA-miRNA-mRNA network and identification of novel potential biomarkers for non-small cell lung cancer
por: Jia Yang, et al.
Publicado: (2021)

Technical Feasibility and Safety of Repeated Computed Tomography–Guided Transthoracic Intratumoral Injection of Gene-Modified Cellular Immunotherapy in Metastatic NSCLC
por: Puja Shahrouki, MD, et al.
Publicado: (2021)